Evaluation of Primary Chemotherapy With Docetaxel Plus Capecitabine in Selected Patients With Newly Diagnosed Localized or Locally Advanced Prostate Cancer

Inclusion Criteria

Patients must have newly diagnosed prostate cancer with at least one of the following
criteria:

- Clinical Stage > T2

- PSA > 15 ng/ml

- Biopsy Gleason's sum > 8

- All patients must have a minimum PSA value of > 5 ng/ml.

- Patients may not have evidence of distant systemic metastasis.

- Patients may not undergo concurrent hormonal, biologic, or chemotherapy.

- Patients may not have prior unanticipated severe reaction to fluoropyrimidine therapy
or known hypersensitivity to 5-fluorouracil.

- Patients with a history of severe reaction to docetaxel or other drugs formulated
with polysorbate 80 will not be eligible.

- Patients may not have an underlying cardiac disease.